Art. 76 Regulation (EU) 2019/6

Reporting and recording of suspected adverse events

In forcesince 11 Dec 2018cited 7×
1.

Competent authorities shall record in the pharmacovigilance database all suspected adverse events which were reported to them and that occurred in the territory of their Member State, within 30 days of receipt of the suspected adverse event report.

2.

Marketing authorisation holders shall record in the pharmacovigilance database all suspected adverse events which were reported to them and that occurred within the Union or in a third country or that have been published in the scientific literature with regard to their authorised veterinary medicinal products, without delay and no later than within 30 days of receipt of the suspected adverse event report.

3.

The Agency may request the holder of a marketing authorisation for centrally authorised veterinary medicinal products, or for nationally authorised veterinary medicinal products in cases where they fall within the scope of a Union interest referral referred to in Article 82, to collect specific pharmacovigilance data additional to the data listed in Article 73(2) and to carry out post-marketing surveillance studies. The Agency shall state in detail the reasons for the request, set an appropriate time limit and inform competent authorities thereof.

4.

Competent authorities may request the holder of a marketing authorisation for nationally authorised veterinary medicinal products to collect specific pharmacovigilance data, additional to the data listed in Article 73(2) and to carry out post-marketing surveillance studies. The competent authority shall state in detail the reasons for the request, set an appropriate time limit and inform other competent authorities and the Agency thereof.

  • Regulation (EU) 2021/128115Law

    … по искане на компетентен орган или на Агенцията в съответствие с член 76, параграфи 3 и 4 от Регламент (ЕС) 2019/6. 2. Отговорният …

  • Tierarzneimittelgesetz38404142Law

    … Zulassung bedürfen, anzuwenden. (2) Das Bundesamt für Sicherheit im Gesundheitswesen erfasst die Meldungen gemäß Art. 76 Abs. 1 und 2 der Verordnung (EU) 2019/6 im Pharmakovigilanz-System gemäß § 75b AMG. (3) Veröffentlichungen …

  • Code de la santé publiquel5141-16r5141-82Law

    … professionnels ; 10° Les règles applicables à la pharmacovigilance des médicaments vétérinaires prévues aux articles 73,76 et 79 du règlement (UE) 2019/6 du 11 décembre 2018 et des médicaments à usage humain utilisés au titre …

  • Regulation (EU) 2024/568Law

    … de 40000 EUR s’applique aux évaluations d’études de surveillance après mise sur le marché au titre de l’article 76, paragraphe 3, du règlement (UE) 2019/6 menées dans plusieurs États membres. 10.2. La redevance est perçue …

  • Vet-PharmakovigilanzV5Law

    … Zulassungsinhaber über unerwünschte Ereignisse im Sinne des Art. 73 Abs. 2 der Verordnung (EU) 2019/6 haben gemäß Art. 76 Abs. 2 der Verordnung (EU) 2019/6 über die Pharmakovigilanz-Datenbank zu erfolgen. (2) Meldungen durch …

  • BMLEHBGebVLaw

  • BMLEHBGebVLaw

    … sind | nach Zeitaufwand 3.3 | Maßnahmen | 3.3.1 | Prüfung und Bewertung weiterer Pharmakovigilanz-Daten gemäß Artikel 76 Absatz 4 der Verordnung (EU) 2019/6 | 790 3.3.2 | Prüfung und Bewertung von Studien zur Überwachung nach dem …